TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oral Fecal Transplant in Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21-75 years of age~* Cirrhosis diagnosed by either of the following in a patient with chronic liver disease (a) Liver Biopsy (b) Radiologic evidence of varices, cirrhosis or portal hypertension (c) Laboratory evidence of platelet count \<100,000 or AST/ALT ratio\>1 (d) Endoscopic evidence of varices or portal gastropathy~* At least two HE episodes, one within the last year but not within the last month (patient can be on lactulose and rifaximin)~* Able to give written, informed consent (mini-mental status exam\>25 at the time of consenting)~Exclusion Criteria:~Disease-related: (1) MELD score\>17 (2) WBC count\<1000 (3) TIPS, non-elective hospitalization or HE within last month (4) on dialysis (5) known untreated, in-situ luminal GI cancers (6) chronic intrinsic GI diseases (ulcerative colitis, Crohn's disease or microscopic colitis, eosinophilic gastroenteritis and celiac disease) Endoscopy-related: (1) Platelet count\<50,000 (2) adverse reactions to sedation (3) lack of driver or other contra-indications Safety-related: (1) Dysphagia (2) History of aspiration, gastroparesis, intestinal obstruction (3) Ongoing absorbable antibiotic use (4) Severe anaphylactic food allergy (5) allergy to ingredients Generally Recognized As Safe in the G3 capsules (glycerol, sodium chloride, hypromellose, gellan gum, titanium dioxide, theobroma oil) (6) Adverse event attributable to prior FMT (7) ASA Class IV or V (8) Pregnant or nursing patients (9) acute illness or fever on the day of planned FMT

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- FMT (Type: EXPERIMENTAL): Fecal Microbiota Transplantation (FMT) capsules
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Intact cognitive status and ability to provide informed consent~* Ability to read and write in English sufficiently to understand and complete study questionnaires~* Age 18-55 inclusive~* Presence of persistent daily low back pain of at least three months duration and of at least a 3/10 in average intensity~Exclusion Criteria:~* Engagement in \> 2 days/wk and \> 60 min/wk of moderate or vigorous intensity activity based on responses to 6 validated survey questions at screening (CDC BRFSS)~* History of renal or hepatic dysfunction~* Current or past alcohol or substance dependence~* A history of PTSD, psychotic, or bipolar disorders~* Chronic pain due to malignancy (e.g., cancer), autoimmune disorders (e.g., rheumatoid arthritis, lupus), or fibromyalgia~* Recent daily opiate use~* Use of any opioid analgesic medications within 72 hours of study participation (confirmed through rapid urine screening conducted prior to study participation)~* Females who are pregnant~* History of cardiovascular disease (including myocardial infarction)~* History of seizure disorder~* Prior allergic reaction/intolerance to morphine or its analogs~* Presence of cardiac disease or any other medical condition that would make engaging in the aerobic exercise manipulation unsafe

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- 6 week aerobic exercise intervention (Type: EXPERIMENTAL): Participants randomly assigned to the exercise condition will complete an 18 session aerobic exercise manipulation supervised by an American College of Sports Medicine-certified personal trainer (3 exercise sessions per week for 6 weeks). Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.
- Normal exercise (control) (Type: ACTIVE_COMPARATOR): Participants assigned to the control condition will not undergo any exercise manipulation during this 6 week period, and will be asked to continue their current activity levels and not engage in any additional exercise activity during the study period. Immediately before and after participating in this intervention arm, participants will undergo laboratory evoked thermal pain response testing with placebo-controlled morphine and naloxone administration to assess mechanisms of exercise-related changes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aggrenox Prevention of Access Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age 18-21 depending on state regulations~* Life expectancy of at least six months~* Chronic renal failure with anticipated start of hemodialysis within six months of enrollment, or current dialysis dependence~* A new or planned arteriovenous (AV) graft placed in any location for the purpose of hemodialysis. (Any type of graft material and any configuration of the access is acceptable).~* The patient is expected to stay at a participating dialysis facility for at least 6 months.~* The patient's physician(s) will allow the patient to participate.~* Ability to give informed consent.~Exclusion Criteria:~* Women must not be pregnant, breastfeeding, or plan to be pregnant during the course of the study.~* The presence of ongoing bleeding.~* The presence of a known bleeding disorder (e.g., hemophilia or von Willebrand's disease).~* Recent bleeding episode requiring transfusion within 12 weeks of entry.~* The presence of acute ulcer disease. Acute ulcer disease is defined as a new diagnosis of peptic disease including esophagitis, gastritis, or ulcer or the initiation of treatment with proton pump inhibitors, H2 blockers or therapy for Helicobacter pylori within three months prior to obtaining consent.~* Known allergy or adverse reaction to Aggrenox or any of its study components (dipyridamole and aspirin).~* Required use of warfarin, dipyridamole, non-steroidal antiinflammatory drugs or other antiplatelet agents other than aspirin.~* Current uncontrolled hypertension with systolic blood pressure in excess of 200 mm Hg or diastolic blood pressure in excess of 115 mm Hg.~* Baseline platelet count less than 75,000/mm3.~* Known advanced liver disease with decompensated cirrhosis, jaundice, ascites or bleeding varices.~* Current problem with substance abuse.~* Concurrent participation in another medical intervention trial.~* Anticipated non-compliance with medical care based on physician judgment.~* Patient refusal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aggrenox (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* A clinical diagnosis of osteoarthritis of the hip or knee~* End-stage degenerative joint disease~* Eligibility for primary unilateral total or partial joint replacement surgery~* Pain level moderate to severe and at such a level as to require daily doses of an opioid analgesic medication~Exclusion Criteria:~* Has a life-long history of seizure disorder or epilepsy~* Had any of the following within the preceding 1 year: mild or moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm~* Had a severe traumatic brain injury within 15 years of screening (consisting of one or more of the following: brain contusion, intracranial hematoma, either unconsciousness or post traumatic amnesia lasting for more than 24 hours)~* Joint pain not associated with gout, fibromyalgia, rheumatoid arthritis, other autoimmune disease~* History of alcohol or drug abuse~* chronic hepatitis B and C or HIV, active hepatitis B and C within 3 months~* Severely impaired renal function or moderately to severely impaired hepatic function~* History of cancer within past 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Tapentadol IR (CG5503) 50mg for 14 days
- 002 (Type: EXPERIMENTAL): Tapentadol IR (CG5503) 75mg for 14 days
- 003 (Type: ACTIVE_COMPARATOR): oxycodone IR 10mg for 14 days
- 004 (Type: PLACEBO_COMPARATOR): placebo 1 capsule for 14 days
- 005 (Type: EXPERIMENTAL): Tapentadol ER (CG5503) flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
- 006 (Type: ACTIVE_COMPARATOR): oxycodone CR flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
- 007 (Type: PLACEBO_COMPARATOR): placebo Tablets and capsules 2 x a day for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hepatitis C virus (HCV) genotype 1a or 1b infection confirmed before randomization~* Documentation of the presence or absence of a NS3 Q80K polymorphism in HCV genotype 1a infected participants before randomization~* Documentation of the IL28B genotype before randomization~* HCV ribonucleic acid level greater than 10,000 IU/mL at screening~* Treatment-experienced participants must have at least 1 documented previous course of interferon-based regimen with or without ribavirin~* Absence of cirrhosis in participants~Exclusion Criteria:~* Evidence of clinical hepatic decompensation (history or current evidence of ascites, bleeding varices or hepatic encephalopathy)~* Infection/co-infection with HCV non-genotype 1a or 1b~* Co-infection with human immunodeficiency virus (HIV) type 1 or type 2 (HIV-1 or HIV-2) (positive HIV-1 or HIV-2 antibodies test at screening)~* Co-infection with hepatitis-B virus (hepatitis-B-surface-antigen positive)~* Previously been treated with any direct acting anti-HCV agent (approved or investigational) for chronic HCV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Simeprevir/Sofosbuvir) (Type: EXPERIMENTAL): 150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally (by mouth) once daily for 12 weeks.
- Arm 2 (Simeprevir/Sofosbuvir) (Type: EXPERIMENTAL): 150 participants will receive 1 capsule of 150 mg simeprevir and 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of A PVP-I Fluoride Varnish

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The subject's parent or legal guardian must provide signed and dated informed consent (parent permission form).~2. The subject's parent or legal guardian of the subject must be willing and able to comply with study requirements.~3. The subject is aged 60-84 months at the time of enrollment.~4. The subject must be in good general health as evidenced by parent report.~Exclusion Criteria:~1. Known allergy to iodine~2. Known allergy to seafood~3. Known hypersensitivity to fluoride varnish~4. Diagnosis of thyroid disease~5. Chronic, prophylactic use of antibiotics~6. Treatment with another investigational drug or other intervention within 30 days preceding the Baseline Visit.

- Gender: ALL
- Minimum Age: 60 Months
- Maximum Age: 84 Months
- Healthy Volunteers: f

Study Arms:
- Test varnish (Type: EXPERIMENTAL): Advantage Anti-Caries Varnish. The active ingredients are Povidone Iodine and Sodium Fluoride .
- Standard varnish (Type: ACTIVE_COMPARATOR): The active control varnish will be the same fluoride varnish without iodine with an appropriate FDA approved food dye added to match the color of the test agent. There will be no difference in the treatment and control varnishes except for the povidone iodine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Participants are eligible to be included in the study only if all of the following criteria apply:~Age and Sex:~1. Male or female participants ≥18 years of age (or the minimum state specific age of consent if \>18), at Screening visit.~   Type of Participant and Disease Characteristics:~2. Participants who are willing and able to comply with daily symptom and voice assessments on the electronic diary application and other study procedures, including self-collection of nasal swabs.~3. Expected to be available for the duration of the study.~Informed Consent:~4. Capable of giving signed informed consent~-~Exclusion Criteria:~Participants are excluded from the study if any of the following criteria apply:~1. Participants who self-report any medical condition, recreational substance use, or medication use which would prevent them from completing study tasks or impair the providing of informed consent, or in the investigator's judgment, make the participant inappropriate for the study.~   Prior/Concomitant Therapy:~2. Participants who have been vaccinated with COVID-19 vaccine or are planning to get vaccinated during study participation.~   Participants can continue to use all other prescription or non-prescription medications.~   Prior/Concurrent Clinical Study Experience:~3. Previous vaccination with any licensed or investigational RSV vaccine or are planning to get vaccinated during study participation.~4. Previous administration with an investigational drug within 30 days of enrollment (or as determined by the local requirement) or planning to participate in an interventional trial during study conduct.~   Diagnostic Assessments:~5. Screening diagnostic assessments are not required for eligibility purposes.~   Other Exclusions:~6. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator including vendors, and their respective family members.~7. Participants who use a mobile device that does not meet the minimum requirements of the Electronic diary.~8. Participants who have previously been enrolled in the study cannot be re-enrolled.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- All participants (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic hand dermatitis, rated as severe by physicians global assessment, present for at least 6 months, that has not responded to the avoidance of allergens and irritants and the use of topical steroids~Exclusion Criteria:~* female of childbearing potential, unless participating in a pregnancy prevention program~* psoriasis~* active major psychiatric condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Persistence of Immunity of PCV13 in Healthy Population Aged 2 Months，7 Months-5 Years

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Those who have participated in the Phase III clinical study of Beijing Minhai PCV13 and have been fully vaccinated with Minhai PCV13;~* An informed consent was required to sign by their legal guardians;~* Volunteers and their legal guardians/caregivers were able to attend the study visit as required by the protocol.~Exclusion Criteria:~* Those who had any administration history of pneumococcal polysaccharide or conjugate vaccine after participating in the Phase III clinical study;~* Prior to enrollment, patients who had a history of pneumococcal infection with one or more of the well-defined PCV13 serotypes;~* The researchers shall judge the other conditions which might be not in compliance with the requirements of this clinical trial.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- 2 months group (Type: OTHER): None
- 7-11 months group (Type: OTHER): None
- 12-23 months group (Type: OTHER): None
- 2-5 years old group (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigate Risperidone for the Treatment of Schizophrenia in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A responsible person must be available to accompany the subject to the site at each visit~* patient must meet the DSM-IV criteria for schizophrenia~Exclusion Criteria:~* Patients with mild, moderate or severe mental retardation~* patients with a known or suspected history of substance dependence~* subjects weighing \<35kg~* subjects who cannot swallow oral tablets

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signed Informed Consent Form and HIPAA document~* Willing and able to comply with all study procedures~* Be at least 18 years of age~* Patient-reported history of dry eye in both eyes~* Demonstrate a positive response when exposed to the Controlled Adverse Environment model~* A negative urine pregnancy test if female of childbearing potential and must use adequate birth control throughout the study period~Exclusion Criteria:~* Any ocular condition that, in the opinion of the Investigator, could affect study parameters including, but not limited to, active ocular infection, ocular inflammation, glaucoma, and/or diabetic retinopathy~* Unwilling to avoid wearing contact lenses for 7 days prior to and for duration of the study period~* Any blood donation or significant loss of blood within 56 days of Visit 1~* Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.~* Use of any topical ophthalmic preparations (including tear substitutes) 72 hrs prior to screening assessments and through the entire study period~* Any significant illness that could interfere with study parameters~* History of laser-assisted in situ keratomileusis (LASIK) or similar type of corneal refractive surgery within 12 months prior to Visit 1, and/or any other ocular surgical procedure within 12 months prior to Visit 1; or any scheduled ocular surgical procedure during the study period.~* Known history of alcohol and/or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Ophthalmic Solution
- 0.1% Lifitegrast (Type: EXPERIMENTAL): Lifitegrast
- 1.0% Lifitegrast (Type: EXPERIMENTAL): Lifitegrast
- 5.0% Lifitegrast (Type: EXPERIMENTAL): Lifitegrast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete